Qiagen N.V. is a global biotechnology company that specializes in providing sample and assay technologies for molecular diagnostics, pharmaceutical development, and academic research. The company develops innovative solutions that enable the extraction, purification, and analysis of nucleic acids, such as DNA and RNA, from various biological samples. Qiagen's products are designed to enhance the speed and accuracy of molecular testing, supporting the detection of diseases, genetic analysis, and the development of personalized medicine. With a strong commitment to advancing scientific research and improving healthcare outcomes, Qiagen collaborates with a range of industries and institutions to deliver reliable and efficient tools for life sciences research and clinical applications. Read More
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and manage ordering support through a single conversational interface.
The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE: QGEN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform to help researchers use AI more effectively in drug discovery.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Qiagen (QGEN) To Contact Him Directly To Discuss Their Options
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
The law firm of Kirby McInerney LLP is investigating potential claims against Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced proposals for its 2026 Annual General Meeting, including plans to appoint co-founder and former Chief Executive Officer Dr. Metin Colpan as Honorary Chairman, the continued renewal of the Supervisory Board and increased returns to shareholders.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to advance its QuantiFERON latent tuberculosis (TB) test with a new fully automated Sample to Insight workflow and a separate AI-enabled risk stratification tool for TB progression, building on growing adoption of Diasorin LIAISON detection systems and a new automation partnership with Inpeco.
LOS ANGELES, May 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or “the Company”) (NYSE: QGEN) for violations of the securities laws.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today reports full results for the first quarter of 2026 in line with the preliminary announcement, showing QIAGEN continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, demonstrating how its portfolio connects sample preparation with multi-omics profiling and genomic data interpretation to support cancer research and molecular diagnostics.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-risk populations.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndromic testing system.
Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN’s entry into high-throughput benchtop automation for sample processing in research laboratories.
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026.
